Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05812274 · ClinicalTrials.gov registry record · NA
Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients
A NA study, sponsored by Columbia University.
- Terminated
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT05812274 is a NA study that was terminated before completion, run by Columbia University. The registered enrollment target is 30 participants.
The verdict
NCT05812274, a NA study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this trial is to study the effectiveness of the AprictyRxTM care service to improve treatment outcomes of ethnic/racial minority N.S.C.L.C. patients receiving standard of care immunotherapy, and reduce the frequency of healthcare system interactions.
Interventions
- OTHER Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2025-10-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05812274
The ClinicalTrials.gov registry entry for NCT05812274 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation is the first listed.
NCT05812274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05812274 about?
NCT05812274 is a clinical study titled "Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients". The purpose of this trial is to study the effectiveness of the AprictyRxTM care service to improve treatment outcomes of ethnic/racial minority N.S.C.L.C. patients receiving standard of care immunotherapy, and reduce the frequency of healthcare system interactions.
What is the current status of trial NCT05812274?
This trial is currently terminated. It is a NA study. The enrollment target is 30 participants. The study started on 2023-05-31. Estimated completion is 2025-10-24.
What interventions are being tested in trial NCT05812274?
The interventions under investigation include: Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation (OTHER).
Who is sponsoring clinical trial NCT05812274?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.